Skip to main content
. 2022 Aug 15:10.1002/acr.24894. Online ahead of print. doi: 10.1002/acr.24894

Figure 1.

Figure 1

Severity of symptoms and solicited symptoms in control subjects versus patients with chronic inflammatory disease. Percentage of participants from each group who had endorsed symptom severity and solicited adverse events within 7 days after doses 1 (A) and 2 (B) of SARS–CoV‐2 vaccine is shown.